Excalipoint Therapeutics
Excalipoint Therapeutics
Developing next-generation T-cell engager therapies for cancer and autoimmune diseases.
About
What does Excalipoint Therapeutics do?
Excalipoint Therapeutics is a biotechnology company focused on developing next-generation T-cell engager (TCE) therapies. The company leverages proprietary technology platforms, including TOPAbody, T-Cell Immune Shield, and TCE Probody, to create highly differentiated treatments for solid tumors and autoimmune diseases.
What is Excalipoint Therapeutics's revenue?
StartupHub estimates Excalipoint Therapeutics's annual revenue at $8.1M (range $2.6M to $34.2M, 34% confidence), based on comparable companies in the sector.
What is Excalipoint Therapeutics's valuation?
StartupHub estimates Excalipoint Therapeutics's effective valuation at $259.7M (range $171.8M to $412.2M, 23% confidence), based on comparable companies in the sector.
How much funding has Excalipoint Therapeutics raised?
Excalipoint Therapeutics has raised a total of $69M in funding. The most recent round on record is Seed.
Where is Excalipoint Therapeutics headquartered?
Excalipoint Therapeutics is headquartered in Shanghai, China.
When was Excalipoint Therapeutics founded?
Excalipoint Therapeutics was founded in 2025.
What industry does Excalipoint Therapeutics operate in?
Excalipoint Therapeutics operates in Biotechnology, Pharmaceuticals, HealthTech, Oncology, Immunology.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Develops and commercializes treatments for central nervous system disorders, including Rett syndrome.
A deep-tech company developing nanorobotic solutions for healthcare, initially targeting dental care applications.
MatrixCode is a research focus at the Freiburg Institute for Advanced Studies (FRIAS) investigating matrisome pathology.
A company focused on privacy, Zcash accumulation, and developing cancer therapeutics.
An entrant is a company tagged Biotechnology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.